Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$178.43 USD

178.43
832,478

-0.90 (-0.50%)

Updated Oct 6, 2025 04:00 PM ET

After-Market: $178.42 -0.01 (-0.01%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What to Expect From Quest Diagnostics (DGX) in Q4 Earnings

by Zacks Equity Research

Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.

    Zacks Equity Research

    Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

    by Zacks Equity Research

    Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

      Zacks Equity Research

      Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS

      by Zacks Equity Research

      Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.

        Zacks Equity Research

        Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory

        by Zacks Equity Research

        Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.

          Zacks Equity Research

          Myriad Genetics Presents Encouraging EndoPredict Test Data

          by Zacks Equity Research

          Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.

            Zacks Equity Research

            Myriad Genetics (MYGN) Presents Positive riskScore Test Data

            by Zacks Equity Research

            Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.

              Zacks Equity Research

              Top Research Reports for Bank of America, Celgene & Goldman Sachs

              by Zacks Equity Research

              Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Celgene (CELG) and Goldman Sachs (GS).

                Zacks Equity Research

                Quest Diagnostics Banks on Buyouts to Expand in Diagnostic

                by Zacks Equity Research

                Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.

                  Zacks Equity Research

                  Quest Diagnostics (DGX) Tops Q3 Earnings, Revenues In Line

                  by Zacks Equity Research

                  Considering hurricanes related financial impact and recently-closed acquisitions, Quest Diagnostics' (DGX) management has revised its guidance for full year 2017.

                    Zacks Equity Research

                    Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?

                    by Zacks Equity Research

                    The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.

                      Zacks Equity Research

                      Is Quest Diagnostics (DGX) a Great Stock for Value Investors?

                      by Zacks Equity Research

                      Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

                        Zacks Equity Research

                        Why Is Quest Diagnostics (DGX) Down 3.9% Since the Last Earnings Report?

                        by Zacks Equity Research

                        Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Zacks Equity Research

                          Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2

                          by Zacks Equity Research

                          Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.

                            Zacks Equity Research

                            Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up

                            by Zacks Equity Research

                            Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.

                              Zacks Equity Research

                              Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up

                              by Zacks Equity Research

                              Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.

                                Zacks Equity Research

                                Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View

                                by Zacks Equity Research

                                Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.

                                  Zacks Equity Research

                                  Quest Diagnostics (DGX) Tops Q2 Earnings, Misses on Sales

                                  by Zacks Equity Research

                                  Quest Diagnostics (DGX) gains in Q2 banking on the acquisition of Med Fusion and ClearPoint.

                                    Zacks Equity Research

                                    Healthcare Q2 Earnings Slated on Jul 25: HCA, UHS & More

                                    by Zacks Equity Research

                                    The healthcare sector continues to benefit from higher enrollments, mergers and acquisitions, partly offset by high expense on account of acquisition integration and investments in technology.

                                      Zacks Equity Research

                                      Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas

                                      by Zacks Equity Research

                                      Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.

                                        Zacks Equity Research

                                        Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?

                                        by Zacks Equity Research

                                        Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.

                                          Zacks Equity Research

                                          3 Excellent Value Picks Amid Political Grind in MedTech

                                          by Zacks Equity Research

                                          While the revised American Health Care Act now only needs the Senate's nod, the scenario is getting increasingly challenging for the Medical Device Space.

                                            Zacks Equity Research

                                            Here's Why You Can Buy Quest Diagnostics Stock Right Now

                                            by Zacks Equity Research

                                            Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.

                                              Zacks Equity Research

                                              Quest Diagnostics to Buy Outreach Lab Service in Cape Cod

                                              by Zacks Equity Research

                                              Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.

                                                Zacks Equity Research

                                                Quest Diagnostics Enhances Blueprint for Athletes Service

                                                by Zacks Equity Research

                                                Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.

                                                  Zacks Equity Research

                                                  Why Quest Diagnostics (DGX) is a Suitable Pick for Investors

                                                  by Zacks Equity Research

                                                  Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.